v ::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::
ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

CLINICAL IMPACTS OF AMBROXOL IN TREATMENT OF THE PATIENTS SUFFERING FROM ASTHMATIC BRONCHITIS

AUTHORS:

Dr Munir Ahmed, Dr Hafiz Naeem Ali, Dr Usama Ibrar

ABSTRACT:

Objective: The purpose of this study is to examine the clinical impacts of ambroxol in treatment of the patients suffering from Asthmatic Bronchitis. Methodology: Total 120 patients who were suffering from Asthmatic Bronchitis and got admission in Sheikh Zayed Hospital Rahim Yar Khan from March 2018 to November 2019, were the participants of this research work. We divided these patients into observation group and control group. There were 60 participants in each group. We performed the treatment of the patients of control group with the conventional method, whereas the treatment of observation group was carried out with ambroxol in addition with conventional method. The comparison was carried out for therapeutic impact, total duration of disappearance of the signs and symptoms and the pulmonary function’s recovery between the patients of both groups. Results: The rate of effectivity of observation group was 96.70% and this rate was 73.30% for patients of control group. Control influence of the patients of observation group was much better as compared to the patients of control group, describing a statistically significant difference (P<0.050). Total duration of the disappearance of symptoms in the patients of observation group was less as compared to the patients of control group. Pulmonary function’s function recovery was better in the patients of observation group as compared to the patients of control group (P<0.050). Conclusion: For the patients of Asthmatic Bronchitis, addition of the ambroxol to conventional method of treatment has the ability to improve the therapeutic impact, lessens the total duration of the disappearance of symptoms and signs and it also promotes the patient’s recovery. KEYWORDS: Conventional, Ambroxol, Asthmatic Bronchitis, Control Group, Observation Group, Pulmonary, Therapeutic.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.